← Search & browse all drugs

lusutrombopag

B02BX07

Forms & Strengths

Tablet: 3 mg

Adult Dosing

3 mg orally once daily with or without food for 7 days
Initiate 8 to 14 days prior to a scheduled invasive procedure
Administer the full 7-day course regardless of platelet count on the day of the procedure

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure

Mechanism of Action

Thrombopoietin (TPO) receptor agonist that interacts with the transmembrane domain of human TPO receptors
Stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased platelet production

Contraindications

None known

Adverse Reactions

Headache
Nausea
Fatigue
Portal vein thrombosis

Drug Interactions

No clinically significant pharmacokinetic drug interactions identified
May increase the risk of thrombosis when used with other agents that cause thrombocytopenia or thrombosis

Curated Content: Needs Vetting Before Put to Clinical Use